Filtered By:
Source: American Heart Journal
This page shows you your search results in order of date. This is page number 11.
Order by Relevance | Date
Total 491 results found since Jan 2013.
An Open-label, 2 x 2 Factorial, Randomized Controlled Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Placebo in Patients with Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention: Rationale and Design of the AUGUSTUS Trial
Publication date: Available online 9 March 2018 Source:American Heart Journal Author(s): Renato D. Lopes, Amit N. Vora, Danny Liaw, Christopher B. Granger, Harald Darius, Shaun G. Goodman, Roxana Mehran, Stephan Windecker, John H. Alexander The optimal antithrombotic strategy for patients with atrial fibrillation (AF) who develop acute coronary syndrome (ACS) and/or the need for percutaneous coronary intervention (PCI) is uncertain. The risk of bleeding is a major concern when oral anticoagulation is required to prevent stroke and concomitant therapy with antiplatelet agents is required to minimize recurrent ischemic even...
Source: American Heart Journal - March 10, 2018 Category: Cardiology Source Type: research
Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial: Study Rationale and Design
Publication date: Available online 7 March 2018 Source:American Heart Journal Author(s): Douglas L. Packer, Daniel B. Mark, Richard A Robb, Kristi Monahan, Tristram Bahnson, Kathleen Moretz, Jeanne Poole, Alice Mascette, Yves Rosenberg, Neal Jeffries, Hussein R. Al-Khalidi, Kerry L. Lee The Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation (CABANA, NCT00911508)(1) trial is testing the hypothesis that the treatment strategy of percutaneous left atrial catheter ablation for the purpose of eliminating atrial fibrillation (AF) is superior to current state-of-the-art pharmacologic therapy. This inte...
Source: American Heart Journal - March 8, 2018 Category: Cardiology Source Type: research
Ticagrelor versus Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: Rationale and Design of the TicagRElor in pAtients with ST elevation myocardial infarction treated with Thrombolysis (TREAT) trial
Publication date: Available online 3 March 2018 Source:American Heart Journal Author(s): Otavio Berwanger, Jose C. Nicolau, Antonio C. Carvalho, Lixin Jiang, Shaun Goodman, Stephen Nicholls, Alexander Parkhomenko, Oleg Averkov, Carlos Tajer, Germán Malaga, Jose F. Kerr Saraiva, Francisco Fonseca, Helio P. Guimaraes, Pedro G.M. de Barros e Silva, Lucas P. Damiani, Denise M. Paisani, Camila M.R. Lasagno, Carolina T. Candido, Nanci Valeis, Diogo D.F. Moia, Leopoldo S. Piegas, Christopher B. Granger, Harvey White, Renato D. Lopes Background The safety and efficacy of ticagrelor in patients with ST-elevation myocardial infarc...
Source: American Heart Journal - March 3, 2018 Category: Cardiology Source Type: research
Is there a role for pharmacokinetic/pharmacodynamic-guided dosing for novel oral anticoagulants?
Publication date: May 2018 Source:American Heart Journal, Volume 199 Author(s): Noel Chan, Philip T. Sager, Jack Lawrence, Thomas's Ortel, Paul Reilly, Scott Berkowitz, Dagmar Kubitza, John Eikelboom, Jeffry Florian, Norman Stockbridge, Martin Rose, Robert Temple, Jonathan H. Seltzer The novel direct oral anticoagulants (NOACs) represent a major advance in oral anticoagulant therapy and are replacing vitamin K antagonists as the preferred options for many indications. Given in fixed doses without routine laboratory monitoring, they have been shown to be at least as effective in reducing thromboembolic stroke as dose-adjus...
Source: American Heart Journal - February 23, 2018 Category: Cardiology Source Type: research
Dual Antiplatelet Therapy for Perioperative Myocardial Infarction Following CABG Surgery
Conclusion One-quarter of CABG patients who had perioperative MI were treated with DAPT. DAPT was not associated with a difference in MI, stroke, or mortality at 30 days, but was associated with fewer re-hospitalizations. Further studies are needed to determine the optimal antiplatelet regimen following perioperative MI. What is already known about this subject? Perioperative myocardial infarction portends poor outcome but optimal management is currently unclear. While dual antiplatelet therapy is standard of care for acute coronary syndrome, its role in perioperative myocardial infarction is unknown. What does this study ...
Source: American Heart Journal - February 11, 2018 Category: Cardiology Source Type: research
Risk of Cardiovascular Events and Incident Atrial Fibrillation in Patients without Prior Atrial Fibrillation: Implications for Expanding the Indications for Anticoagulation
Conclusions Patients without diagnosed AF but with certain risk factors were at a particularly high cardiovascular risk and may require new prevention approaches. In addition to the ongoing trials, future trials in other high-risk populations, e.g., diabetes and chronic kidney disease may be warranted.
Source: American Heart Journal - February 10, 2018 Category: Cardiology Source Type: research
Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD)
Conclusions VOYAGER PAD is evaluating the efficacy of rivaroxaban added to background antiplatelet therapy to reduce major cardiovascular and limb ischemic vascular outcomes in the high-risk population of PAD patients undergoing peripheral revascularization.
Source: American Heart Journal - February 3, 2018 Category: Cardiology Source Type: research
Transcatheter closure of patent foramen ovale following cryptogenic stroke: An updated meta-analysis of randomized controlled trials
Conclusions Transcatheter closure is associated with a significant reduction in the risk of stroke compared to medical management at the expense of an increased risk of atrial arrhythmias.
Source: American Heart Journal - February 1, 2018 Category: Cardiology Source Type: research
Shared Decision-Making Tool for Thromboprophylaxis in Atrial Fibrillation – A Feasibility Study
Conclusions A shared decision-making interaction, facilitated by an AFSDM can significantly improve multiple measures of decision-making quality, leading to improved medication adherence and patient satisfaction.
Source: American Heart Journal - January 17, 2018 Category: Cardiology Source Type: research
The Optimal Anti-Coagulation for Enhanced-Risk Patients Post –Catheter Ablation for Atrial Fibrillation (OCEAN) trial
The objective was to assess whether rivaroxaban is superior to acetylsalicylic acid (ASA) in reducing the risk of clinically overt stroke, systemic embolism, or covert stroke among patients without apparent recurrent atrial arrhythmias for at least 1 year after their most recent AF ablation procedure. Methods/design A prospective, multicenter, open-label, randomized trial with blinded assessment of outcomes is under way (NCT02168829). Atrial fibrillation patients with at least 1 stroke risk factor (as defined by the CHA2DS2-VASc score) and without known atrial arrhythmia recurrences for at least 12 months after ablation ar...
Source: American Heart Journal - January 17, 2018 Category: Cardiology Source Type: research
Rationale and Design of the Statins Evaluation in Coronary procedUres and REvascularization: The SECURE-PCI Trial
Publication date: Available online 8 January 2018 Source:American Heart Journal Author(s): Otavio Berwanger, Pedro G.M. de Barros e Silva, Frederico Toledo Campo Dall Orto, Pedro Beraldo de Andrade, Igor Ribeiro de Castro Bienert, Carlos Eduardo Bosso, José Mangione, Carisi Anne Polanczyk, Amanda Sousa, Renato Kalil, Luciano de Moura Santos, Andrei C. Sposito, Rafael L. Rech, Antonio Carlos Sobral Sousa, Felipe Baldissera, Bruno Ramos Nascimento, Isabella de Andrade Jesuíno, Eliana Vieira Santucci, Lucas Petri Daminani, Ligia N Laranjeira, Juliana A Borges de Oliveira, Roberto R Giraldez, Alexandre Biasi Cavalcanti, Sab...
Source: American Heart Journal - January 9, 2018 Category: Cardiology Source Type: research
Efficacy and Safety of Dabigatran Compared with Warfarin in Patients with Atrial Fibrillation in Relation to Renal Function Over Time – A RE-LY trial analysis
Conclusions In AF, WRF was associated with a higher risk of death and major bleeding. The efficacy and safety profile of dabigatran compared to warfarin was similar irrespective of renal function changes over time. Dabigatran 110 mg showed a greater relative risk reduction of major bleeding in patients with normal renal function during follow-up.
Source: American Heart Journal - January 6, 2018 Category: Cardiology Source Type: research
Changes in glomerular filtration rate and outcomes in patients with atrial fibrillation
Conclusions Rates of IS/TE, mortality and bleeding increased with worsening eGFR >4.81 ml/min/1.73 m2. Worsening eGFR was an independent predictor of IS/TE and of bleeding, and a better predictor of IS/TE than renal impairment in AF.
Source: American Heart Journal - December 31, 2017 Category: Cardiology Source Type: research
Preoperative factors associated with worsening in health-related quality of life following coronary artery bypass grafting in the ROOBY trial
Conclusions Among VA patients, less than 20% experienced worse HRQL 1year after CABG. For patients with low symptom burden at baseline, diabetes, smoking, depression, PVD, COPD, and a prior stroke, clinicians should be more cautious in pre-CABG counseling as to their anticipated HRQL improvements.
Source: American Heart Journal - December 25, 2017 Category: Cardiology Source Type: research
Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical endpoints - Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC)
Conclusion The ICPC aims to identify new loci influencing clopidogrel efficacy by using state-of-the-art genetic techniques in a large cohort of clopidogrel-treated patients in order to better understand the genetic basis of on-treatment response variability.
Source: American Heart Journal - December 18, 2017 Category: Cardiology Source Type: research
